813 related articles for article (PubMed ID: 33541288)
1. Efficacy of extracranial stereotactic body radiation therapy (SBRT) added to standard treatment in patients with solid tumors (breast, prostate and non-small cell lung cancer) with up to 3 bone-only metastases: study protocol for a randomised phase III trial (STEREO-OS).
Thureau S; Marchesi V; Vieillard MH; Perrier L; Lisbona A; Leheurteur M; Tredaniel J; Culine S; Dubray B; Bonnet N; Asselain B; Salleron J; Faivre JC
BMC Cancer; 2021 Feb; 21(1):117. PubMed ID: 33541288
[TBL] [Abstract][Full Text] [Related]
2. Rationale of technical requirements for NRG-BR001: The first NCI-sponsored trial of SBRT for the treatment of multiple metastases.
Al-Hallaq HA; Chmura S; Salama JK; Winter KA; Robinson CG; Pisansky TM; Borges V; Lowenstein JR; McNulty S; Galvin JM; Followill DS; Timmerman RD; White JR; Xiao Y; Matuszak MM
Pract Radiat Oncol; 2016; 6(6):e291-e298. PubMed ID: 27345129
[TBL] [Abstract][Full Text] [Related]
3. A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS).
Hasan H; Deek MP; Phillips R; Hobbs RF; Malek R; Radwan N; Kiess AP; Dipasquale S; Huang J; Caldwell T; Leitzel J; Wendler D; Wang H; Thompson E; Powell J; Dudley S; Deville C; Greco SC; Song DY; DeWeese TL; Gorin MA; Rowe SP; Denmeade S; Markowski M; Antonarakis ES; Carducci MA; Eisenberger MA; Pomper MG; Pienta KJ; Paller CJ; Tran PT
BMC Cancer; 2020 Jun; 20(1):492. PubMed ID: 32487038
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Safety of Stereotactic Body Radiotherapy for the Treatment of Patients With Multiple Metastases: Findings From the NRG-BR001 Phase 1 Trial.
Chmura S; Winter KA; Robinson C; Pisansky TM; Borges V; Al-Hallaq H; Matuszak M; Park SS; Yi S; Hasan Y; Bazan J; Wong P; Yoon HA; Horton J; Gan G; Milano MT; Sigurdson ER; Moughan J; Salama JK; White J
JAMA Oncol; 2021 Jun; 7(6):845-852. PubMed ID: 33885704
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic ablative radiotherapy for the comprehensive treatment of 1-3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial.
Olson R; Mathews L; Liu M; Schellenberg D; Mou B; Berrang T; Harrow S; Correa RJM; Bhat V; Pai H; Mohamed I; Miller S; Schneiders F; Laba J; Wilke D; Senthi S; Louie AV; Swaminath A; Chalmers A; Gaede S; Warner A; de Gruijl TD; Allan A; Palma DA
BMC Cancer; 2020 May; 20(1):380. PubMed ID: 32370765
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial.
Lieverse RIY; Van Limbergen EJ; Oberije CJG; Troost EGC; Hadrup SR; Dingemans AC; Hendriks LEL; Eckert F; Hiley C; Dooms C; Lievens Y; de Jong MC; Bussink J; Geets X; Valentini V; Elia G; Neri D; Billiet C; Abdollahi A; Pasquier D; Boisselier P; Yaromina A; De Ruysscher D; Dubois LJ; Lambin P
BMC Cancer; 2020 Jun; 20(1):557. PubMed ID: 32539805
[TBL] [Abstract][Full Text] [Related]
7. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study.
Tsai CJ; Yang JT; Shaverdian N; Patel J; Shepherd AF; Eng J; Guttmann D; Yeh R; Gelblum DY; Namakydoust A; Preeshagul I; Modi S; Seidman A; Traina T; Drullinsky P; Flynn J; Zhang Z; Rimner A; Gillespie EF; Gomez DR; Lee NY; Berger M; Robson ME; Reis-Filho JS; Riaz N; Rudin CM; Powell SN;
Lancet; 2024 Jan; 403(10422):171-182. PubMed ID: 38104577
[TBL] [Abstract][Full Text] [Related]
8. Unresectable Intermediate-Size (3-5 cm) Colorectal Liver Metastases: Stereotactic Ablative Body Radiotherapy Versus Microwave Ablation (COLLISION-XL): Protocol of a Phase II/III Multicentre Randomized Controlled Trial.
van der Lei S; Dijkstra M; Nieuwenhuizen S; Schulz HH; Vos DJW; Versteeg KS; Buffart TE; Swijnenburg RJ; de Vries JJJ; Bruynzeel AME; van den Tol MP; Scheffer HJ; Puijk RS; Haasbeek CJA; Meijerink MR;
Cardiovasc Intervent Radiol; 2023 Aug; 46(8):1076-1085. PubMed ID: 37430016
[TBL] [Abstract][Full Text] [Related]
9. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study.
Milano MT; Katz AW; Zhang H; Okunieff P
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):878-86. PubMed ID: 22172903
[TBL] [Abstract][Full Text] [Related]
10. [Extracranial stereotactic radiotherapy for early-stage non-small cell lung cancer and oligometastases].
Riesterer O
Praxis (Bern 1994); 2013 Oct; 102(21):1309-16. PubMed ID: 24129299
[TBL] [Abstract][Full Text] [Related]
11. Canadian Phase III Randomized Trial of Stereotactic Body Radiotherapy Versus Conventionally Hypofractionated Radiotherapy for Stage I, Medically Inoperable Non-Small-Cell Lung Cancer - Rationale and Protocol Design for the Ontario Clinical Oncology Group (OCOG)-LUSTRE Trial.
Swaminath A; Wierzbicki M; Parpia S; Wright JR; Tsakiridis TK; Okawara GS; Kundapur V; Bujold A; Ahmed N; Hirmiz K; Kurien E; Filion E; Gabos Z; Faria S; Louie AV; Owen T; Wai E; Ramchandar K; Chan EK; Julian J; Cline K; Whelan TJ
Clin Lung Cancer; 2017 Mar; 18(2):250-254. PubMed ID: 27876603
[TBL] [Abstract][Full Text] [Related]
12. Pain Response After Stereotactic Body Radiation Therapy Versus Conventional Radiation Therapy in Patients With Bone Metastases-A Phase 2 Randomized Controlled Trial Within a Prospective Cohort.
Pielkenrood BJ; van der Velden JM; van der Linden YM; Bartels MMT; Kasperts N; Verhoeff JJC; Eppinga WSC; Gal R; Verlaan JJ; Verkooijen HML
Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):358-367. PubMed ID: 33333200
[TBL] [Abstract][Full Text] [Related]
13. Oligometastases: history of a hypothesis.
Milano MT; Biswas T; Simone CB; Lo SS
Ann Palliat Med; 2021 May; 10(5):5923-5930. PubMed ID: 32279519
[TBL] [Abstract][Full Text] [Related]
14. Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence.
Decaestecker K; De Meerleer G; Lambert B; Delrue L; Fonteyne V; Claeys T; De Vos F; Huysse W; Hautekiet A; Maes G; Ost P
Radiat Oncol; 2014 Jun; 9():135. PubMed ID: 24920079
[TBL] [Abstract][Full Text] [Related]
15. Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with "curative" intent.
Buglione M; Jereczek-Fossa BA; Bonù ML; Franceschini D; Fodor A; Zanetti IB; Gerardi MA; Borghetti P; Tomasini D; Di Muzio NG; Oneta O; Scorsetti M; Franzese C; Romanelli P; Catalano G; Dell'Oca I; Beltramo G; Ivaldi GB; Laudati A; Magrini SM; Antognoni P;
Lung Cancer; 2020 Mar; 141():1-8. PubMed ID: 31926440
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy".
Rieber J; Streblow J; Uhlmann L; Flentje M; Duma M; Ernst I; Blanck O; Wittig A; Boda-Heggemann J; Krempien R; Lohaus F; Klass ND; Eble MJ; Imhoff D; Kahl H; Petersen C; Gerum S; Henkenberens C; Adebahr S; Hass P; Schrade E; Wendt TG; Hildebrandt G; Andratschke N; Sterzing F; Guckenberger M
Lung Cancer; 2016 Jul; 97():51-8. PubMed ID: 27237028
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.
Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A
Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848
[TBL] [Abstract][Full Text] [Related]
18. Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial.
Decaestecker K; De Meerleer G; Ameye F; Fonteyne V; Lambert B; Joniau S; Delrue L; Billiet I; Duthoy W; Junius S; Huysse W; Lumen N; Ost P
BMC Cancer; 2014 Sep; 14():671. PubMed ID: 25223986
[TBL] [Abstract][Full Text] [Related]
19. Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer.
Conibear J; Chia B; Ngai Y; Bates AT; Counsell N; Patel R; Eaton D; Faivre-Finn C; Fenwick J; Forster M; Hanna GG; Harden S; Mayles P; Moinuddin S; Landau D
BMJ Open; 2018 Apr; 8(4):e020690. PubMed ID: 29666135
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic radiosurgery combined with anlotinib for limited brain metastases with perilesional edema in non-small cell lung cancer: Rvision-001 study protocol.
Wang Y; Wang X; Guan Y; Song Y; Zhuang H; Wang E
Thorac Cancer; 2020 May; 11(5):1361-1364. PubMed ID: 32163662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
